Drugs / Buprenorphine/naloxone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02294253 | Sep 2014 → Dec 2017 | opiate dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Buprenorphine/naloxone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02294253 ↗ |
| Route | Oral | “30 day oral Buprenorphine/naloxone” NCT02294253 ↗ |